한국형 양극성 장애 약물치료 알고리듬 2022: 소아/청소년 (Korean Medication Algorithm Project for Bipolar Disorder 2022: Children and Adolescents)

서지정보

· 발행기관 : 대한신경정신의학회
· 수록지 정보 : 신경정신의학 / 61권 / 3호 / 224 ~ 236페이지
· 저자명 : 양찬모, 박원명, 우영섭, 정종현, 서정석, 추일한, 김원, 이정구, 정명훈, 전덕인, 박성용, 손인기, 김문두, 윤보현, 심세훈

초록

Objectives The objective of this study was to revise the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2022: children and adolescents. Methods We performed a survey, using a questionnaire comprising 23 questions according to various situations facing children and adolescents with bipolar disorders. A total of 40 of the 60 experts in child and adolescent psychiatry responded to the survey. Results The first-line pharmacotherapeutic strategies for manic and depressive episodes in children with bipolar disorders were a combination of mood stabilizer (MS) and atypical antipsy chotics (AAP). The first-line medications selected for these children were aripiprazole (treatme f choice, TOC) and risperidone. The first-line pharmacotherapeutic strategies for manic epi sodes in adolescents were a combination of MS and an AAP (TOC), monotherapy with MS, andmonotherapy with an AAP. Lithium, valproate, aripiprazole, risperidone, and quetiapine were se lected as first-line medications for these adolescents. First-line pharmacotherapeutic strategiesfor depressive episodes in adolescents were a combination of MS and an AAP, monotherapywith MS, and monotherapy with an AAP. The first-line pharmacotherapeutic strategies for thedepressive episodes in adolescents at high risk for bipolar disorder were a combination of MSand AAP and monotherapy with an AAP. Lithium, valproate, aripiprazole (TOC), quetiapine, andrisperidone were selected as first-line medications for the treatment of depressive episodes inadolescents with bipolar disorder.
Conclusion It is expected that the present KMAP-BP 2022: children and adolescents will givethe direction and be usefully applied by clinicians to treat children and adolescents with bipolardisorders.

영어초록

Objectives The objective of this study was to revise the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2022: children and adolescents. Methods We performed a survey, using a questionnaire comprising 23 questions according to various situations facing children and adolescents with bipolar disorders. A total of 40 of the 60 experts in child and adolescent psychiatry responded to the survey. Results The first-line pharmacotherapeutic strategies for manic and depressive episodes in children with bipolar disorders were a combination of mood stabilizer (MS) and atypical antipsy chotics (AAP). The first-line medications selected for these children were aripiprazole (treatme f choice, TOC) and risperidone. The first-line pharmacotherapeutic strategies for manic epi sodes in adolescents were a combination of MS and an AAP (TOC), monotherapy with MS, andmonotherapy with an AAP. Lithium, valproate, aripiprazole, risperidone, and quetiapine were se lected as first-line medications for these adolescents. First-line pharmacotherapeutic strategiesfor depressive episodes in adolescents were a combination of MS and an AAP, monotherapywith MS, and monotherapy with an AAP. The first-line pharmacotherapeutic strategies for thedepressive episodes in adolescents at high risk for bipolar disorder were a combination of MSand AAP and monotherapy with an AAP. Lithium, valproate, aripiprazole (TOC), quetiapine, andrisperidone were selected as first-line medications for the treatment of depressive episodes inadolescents with bipolar disorder.
Conclusion It is expected that the present KMAP-BP 2022: children and adolescents will givethe direction and be usefully applied by clinicians to treat children and adolescents with bipolardisorders.

참고자료

· 없음